Another phase 3 EMERALD-1 trial demonstrated that the combination of TACE with anti-PD-L1 antibody (durvalumab) and bevacizumab significantly improved the PFS (median, 15 vs. 8.2 months; HR (hazard ratio), 0.77; P = 0.032) in unresectable HCC patients compared with TACE alone; the PFS after treatment with TACE plus durvalumab was not significant (median: 10 vs. 8.2 months, HR 0.94, P = 0.638) (142). The gene discussed is CD274; the disease is hepatocellular carcinoma.